A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis
- Registration Number
- NCT05300932
- Lead Sponsor
- Tongji Hospital
- Brief Summary
Systemic Sclerosis (Ssc) is a rare, systemic autoimmune disease characterized by skin fibrosis and vasculopathy. In addition to the skin, it is a heterogeneous disease that affects multiple organs, including the musculoskeletal, cardiac, pulmonary, and gastrointestinal systems. Patients may experience many symptoms such as pain, fatigue, dyspnea, impaired hand function, dry mouth, and difficulty sleeping. As a result of these symptoms, these patients may experience a decrease in activities of daily living, physical activity level and quality of life, while psychological problems such as anxiety and depression may increase.
- Detailed Description
This is a 48 weeks, prospective, double-blind, controlled study. The specific objectives of this study are to:
1. Determine whether Baricitinib is effective and safe in the treatment of patients with diffuse cutaneous (dc)SSc when compared to patients treated with CTX. In this study, stand of care of GC is permitted to use.
2. Determine whether Baricitinib is more effective than CTX, as measured by change in CRISS, which is a composite outcome measure provisionally endorsed by the ACR for scleroderma clinical trials. It incorporates change in the mRSS, FVC percent predicted, physician and patient global assessments, and HAQ-DI. Additionally, hemoglobin corrected diffusion capacity (DLCO), Medsger Severity Scale (MSS), and by other physician and patient derived outcome measures will be used.
3. Determine the biological activity of Baricitinib vs CTX as assessed by effect on histology of skin, gene expression of skin and blood, change in B-Cell profiles including assessment of B regulatory cells, and effect on serological and cutaneous biomarkers of disease activity.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
- Diagnosis of Systematic Sclerosis (SSc), as defined using the 2013 American College of Rheumatology/ European Union League Against Rheumatism classification of SSc
- Diffuse Systemic Sclerosis (dcSSc) as defined by LeRoy and Medsger
- Disease duration of ≤ 36 months (defined as time from the first non-Raynaud phenomenon manifestation)
- For disease duration of ≤ 18 months: ≥ 10 and ≤ 35 mRSS units at the screening visit
- For disease duration of >18-36 months: ≥ 15 and ≤ 45 mRSS units at the screening visit and one of the following:
1)Increase ≥ 3 in mRSS units compared with the last visit within previous 1-6 months 2)Involvement of one new body area with ≥ 2 mRSS units compared with the last visit within the previous 1-6 months 3)Involvement of two new body areas with ≥ 1 mRSS units compared with the last visit within the previous 1-6 months 4)Presence of 1 or more Tendon Friction Rub 6.Age ≥ 18 years at the screening visit 7.If female of childbearing potential, the patient must have a negative pregnancy test at screening and baseline visits 8.Oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) and NSAIDs are permitted if the patient is on a stable dose regimen for 2 weeks prior to and including the baseline visit.
9.ACE inhibitors, calcium-channel blockers, proton-pump inhibitors, and/or oral vasodilators are permitted if the patient is on a stable dose for ≥ 2 weeks prior to and including the baseline visit.
- Rheumatic disease other than dcSSc; it is acceptable to include patients with fibromyalgia and scleroderma-associated myopathy
- Limited cutaneous systemic sclerosis or sine scleroderma at the screening visit
- Major surgery (including joint surgery) within 8 weeks prior to screening visit
- Infected ulcer prior to treatment
- Treatment with any investigational agent within ≤ 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of the baseline visit
- Previous treatment with cell-depleting therapies, including investigational agents, including but not limited to, CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19, and ABA
- Anti-CD20 within 12 months prior to baseline visit.
- Use of Intravenous Immunoglobulin (IVIG) within 12 weeks prior to baseline visit
- Previous treatment with chlorambucil, bone marrow transplantation, or total lymphoid irradiation
- Immunization with a live/attenuated vaccine within ≤ 4 weeks prior to the baseline visit
- Treatment with methotrexate, hydroxychloroquine, cyclosporine A, azathioprine, mycophenolate mofetil rapamycin, colchicine, or D-penicillamine, within≤ 4 weeks prior to the baseline visit
- Treatment with etanercept within ≤ 2 weeks, infliximab, certolizumab, golimumab, ABA or adalimumab within ≤ 8 weeks, anakinra within ≤ 1 week prior to the baseline visit
- Pulmonary disease with FVC ≤ 50% of predicted, or DLCO (uncorrected for hemoglobin ) ≤ 40% of predicted at the screening visit
- Pulmonary arterial hypertension (PAH) as determined by right heart catheterization or on PAH approved medications for PAH. It is acceptable to use PDFE-5 inhibitors for Raynaud's and digital ulcers.
- Subjects at risk for tuberculosis (TB). Specifically excluded from this study will be participants with a history of active TB within the last 3 years, even if it was treated; a history of active TB greater than 3 years ago, unless there is documentation that the prior anti-TB treatment was appropriate in duration and type; current clinical, radiographic, or laboratory evidence of active TB; and latent TB that was not successfully treated (≥ 4 weeks).
- Positive for hepatitis B surface antigen prior to the baseline visit
- Positive for hepatitis C antigen, if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay prior to baseline visit
- Subjects at risk for tuberculosis (TB). Specifically excluded from this study will be participants with a history of active TB within the last 3 years, even if it was treated; a history of active TB greater than 3 years ago, unless there is documentation that the prior anti-TB treatment was appropriate in duration and type; current clinical, radiographic, or laboratory evidence of active TB; and latent TB that was not successfully treated (≥ 4 weeks).
- Any of the following at the screening visit: Hemoglobin <8 g/dL; ANC < 1,000/mm3 (<1 x 109/L); platelets < 100,000/mm3 (<100 x 109/L); serum creatinine > 2 x ULN; serum ALT or AST > 2 x ULN
- Severe skin thickening (mRSS 3) on the inner aspects of thighs, upper arms, or abdomen
- Patients with a history of anaphylaxis to Baricitinib or cyclophosphamide
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cyclophosphamide Cyclophosphamide Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period. Baricitinib 4mg Baricitinib 4mg of oral Baricitinib everyday for 48 weeks.
- Primary Outcome Measures
Name Time Method Change in modified Rodnan skin score (mRSS) at week 24 24 weeks Change in modified Rodnan skin score (mRSS) at week 24 performed by the same investigator at week 0 and week 24 and the change in mRSS will be calculated following the formula: ΔmRSS= mRSSw24 - mRSSw0.
To measure mRSS, skin thickness of the patient is rated by palpation at each of 17 anatomic sites using a scale of 0-3 (0 = normal skin; 1= mild thickness; 2= moderate thickness; 3=severe thickness with an inability to pinch the skin into a fold). The scores at each site are summed with a minimum of 0 and a maximum of 51 (17 sites)
- Secondary Outcome Measures
Name Time Method Proportion of patients who improved mRSS at 12，24，32，40，48 weeks 12，24，32，40，48 weeks Proportion of patients who improved mRSS at 12，24，32，40，48 weeks
SSc disease activity 12，24，32，40，48 weeks Physicians visual analogue scale range from 0 (min) to 10 (max) - 0=no activity, 10=maximum activity Patients visual analogue scale range from 0 (min) to 10 (max) - 0=no activity, 10=maximum activity
Change in modified Rodnan skin score at 12，24，32，40，48 weeks 12，24，32，40，48 weeks Change in modified Rodnan skin score at 12，24，32，40，48 weeks
Change in the Combined Response Index in Diffuse Systemic Sclerosis (CRISS) score 24，48 weeks composite response index
Short Form-36 (SF-36) health questionnaire 0, 12，24，32，40，48 weeks self-administered questionnaire of 36 items assessing the following 8 domains : physical functioning, bodily pain, role limitations attributable to physical health problems, general health perceptions, mental health, role limitations to emotional problems, vitality and social functioning (scale from 0 to 100)
EurolQol-5Domain (EQ-5D) health questionnaire 0, 12，24，32，40，48 weeks self reported measure of quality of life - (scale from 0 to 100)
Incidence of death 24 & 48 weeks Incidence of death
Health Assessment Questionnaire Disability Index (HAQ-DI) scale 0, 12，24，32，40，48 weeks self administered 20 questions- score range from 0 (no disability) to 3 (severe disability)
Incidence of Adverse Events 24 & 48 weeks according to the Common Terminology Criteria for Adverse Events (CTCAE) toxicity grading scale
Incidence of Severe Adverse Events 24 & 48 weeks according to the Common Terminology Criteria for Adverse Events (CTCAE) toxicity grading scale
Proportion of patients with an active disease according to the European scleroderma trials and research group (EUSTAR)SSc activity score at 12，24，48 weeks 12，24，32，40，48 weeks EUSTAR SSc activity index score from 0 to 10 - a cut-off ≥ 2.5 identifies patients with active disease
Trial Locations
- Locations (2)
Department of RheumatologyTongji Hospital
🇨🇳Wuhan, Hubei, China
Tongji Hospital
🇨🇳Wuhan, Hubei, China